Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Descripció completa

Dades bibliogràfiques
Autors principals:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Format:	Journal article
Idioma:	English
Publicat:	Elsevier 2020

Ítems similars

Lipid-modifying agents, from statins to PCSK9 inhibitors
per: Preiss, D, et al.
Publicat: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
per: Sanjiv Gupta
Publicat: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
per: Caleyachetty, R, et al.
Publicat: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
per: K. O. Shnaider, et al.
Publicat: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
per: Konstantinos Koskinas, et al.
Publicat: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
per: Christopher LaFratte, et al.
Publicat: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
per: Nissen, SE, et al.
Publicat: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
per: Mohsin Haseeb, et al.
Publicat: (2023-03-01)

JACC: Asia
per: Jian'an Wang, MD, PhD
Publicat: (2021-06-01)

JACC: Asia
per: Valentin Fuster, MD, PhD, et al.
Publicat: (2021-06-01)

The PCSK9 decade
per: Gilles Lambert, et al.
Publicat: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
per: Mbikay Majambu, et al.
Publicat: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
per: Shuai Wang, et al.
Publicat: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
per: Ying Xiao, et al.
Publicat: (2022-11-01)

PCSK9 inhibitors
per: Baris Gencer, et al.
Publicat: (2015-04-01)

JACC: Case Reports
per: Julia Grapsa, MD, PhD, et al.
Publicat: (2019-08-01)

JACC: Case Reports
per: Julia Grapsa, MD, PhD, et al.
Publicat: (2020-06-01)

JACC: Case Reports
per: Purvi Parwani, MBBS, MPH, et al.
Publicat: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
per: Preiss, D, et al.
Publicat: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
per: Maram H. Abduljabbar
Publicat: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
per: Sliz, E, et al.
Publicat: (2018)

Vision for JACC: Case Reports
per: Julia Grapsa, MD, PhD
Publicat: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
per: Armitage, J, et al.
Publicat: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
per: A. V. Blokhina, et al.
Publicat: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
per: Markus Mohaupt
Publicat: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
per: Bijay Mukesh Jeswani, et al.
Publicat: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
per: Naoto Kuyama, et al.
Publicat: (2021-06-01)

Introducing JACC: Basic to Translational Science
per: Douglas L. Mann, MD, et al.
Publicat: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
per: Weiqi Zeng, et al.
Publicat: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
per: Preiss, D, et al.
Publicat: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
per: Dennis T. Ko, et al.
Publicat: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
per: Tiny Nair
Publicat: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
per: Martin Jozef Péč, et al.
Publicat: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
per: Caroline Coppinger BS, et al.
Publicat: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
per: L. Castilla-Guerra, et al.
Publicat: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
per: A. Yu. Filatova, et al.
Publicat: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
per: Marianna Puccini, et al.
Publicat: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
per: Blom DJ, et al.
Publicat: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
per: Zinan ZHAO, et al.
Publicat: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
per: Lillian Smith, et al.
Publicat: (2016-03-01)